Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The China State Food and Drug Administration (SFDA) has approved 3SBio's application to conduct the China arm of the multi-center Phase III trial of voclosporin.
Subscribe to our email newsletter
Voclosporin is a new generation calcineurin inhibitor licensed from Isotechnika Pharma.
According to the approved protocol, the study will be a Phase III, randomized, multi-center, concentration-controlled comparison study on renal transplant patients.
The company expects to begin patient enrollment in the third quarter of 2012.
3SBio is a biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.